FYB206 clinical trials

A Multicenter, Randomized, Double-blind Trial to Demonstrate Similar Efficacy, Safety, and Immunogenicity of FYB206 (Keytruda Biosimilar Candidate) in Comparison to Keytruda (Pembrolizumab) as an Add-on to Chemotherapy in Treatment-naïve Patients with Metastatic Non-squamous Non-small Cell Lung Cancer (LOTUS)

This study is comparing a new medication called FYB206 to a commonly used lung cancer drug, Keytruda. We want to see if FYB206 works just as well and is as safe for people with a certain type of advanced non-small cell lung cancer when given with chemotherapy.